Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Retained Earnings (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Retained Earnings for 9 consecutive years, with -$4.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings fell 447.88% year-over-year to -$4.9 million, compared with a TTM value of -$4.9 million through Sep 2025, down 447.88%, and an annual FY2024 reading of -$29.2 million, up 96.68% over the prior year.
  • Retained Earnings was -$4.9 million for Q3 2025 at Autolus Therapeutics, down from $862000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $862000.0 in Q2 2025 and bottomed at -$1.2 billion in Q1 2025.
  • Average Retained Earnings over 5 years is -$442.8 million, with a median of -$298.6 million recorded in 2022.
  • The sharpest move saw Retained Earnings plummeted 2700.31% in 2024, then surged 100.09% in 2025.
  • Year by year, Retained Earnings stood at -$8.6 million in 2021, then plummeted by 353.89% to -$38.9 million in 2022, then plummeted by 2158.63% to -$878.6 million in 2023, then skyrocketed by 96.68% to -$29.2 million in 2024, then surged by 83.14% to -$4.9 million in 2025.
  • Business Quant data shows Retained Earnings for AUTL at -$4.9 million in Q3 2025, $862000.0 in Q2 2025, and -$1.2 billion in Q1 2025.